May 21, 2020 / 8:25 PM / 9 days ago

BRIEF-Xenon Pharmaceuticals Posts Quarterly Loss Per Share $0.22

May 21 (Reuters) - Xenon Pharmaceuticals Inc:

* XENON PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

* ADDITIONAL FDA FEEDBACK SUPPORTS COMMENCEMENT OF XEN496 PHASE 3 CLINICAL TRIAL IN 2020

* CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2020 WERE $229.7 MILLION

* QTRLY LOSS PER SHARE $0.22

* Q1 EARNINGS PER SHARE VIEW $-0.32 — REFINITIV IBES DATA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below